1α,25(OH)2D3 Induces Actin Depolymerization in Endometrial Carcinoma Cells by Targeting RAC1 and PAK1

Area of Science:

• Cell Biology
• Molecular Endocrinology
• Cancer Research

Background:

• Cell proliferation and motility depend on actin cytoskeleton remodeling, regulated by pathways involving ras-related C3 botulinum toxin substrate 1 (RAC1), p21 protein-activated kinase 1 (PAK1), and actin related protein 2 (ARP2).
• 1α,25-Dihydroxy-Vitamin D3 (1α,25(OH)2D3), a vitamin D metabolite, influences tumor cell proliferation, beyond its known roles in calcium and phosphorus metabolism.

Purpose of the Study:

• To investigate the effects of 1α,25(OH)2D3 on the actin cytoskeleton in Ishikawa cells, a model for well-differentiated endometrial carcinoma.
• To elucidate the molecular mechanisms underlying vitamin D3's impact on actin dynamics in endometrial cancer.

Main Methods:

• Confocal microscopy was employed to visualize the actin cytoskeleton.
• Western blotting and flow cytometry were used to quantify the globular to filamentous actin ratio.
• Quantitative real-time PCR (qRT-PCR) and immunoblotting assessed transcript and protein levels of key regulatory molecules.

Main Results:

• Treatment with 1α,25(OH)2D3 (100 nM for 24 hours) significantly reduced RAC1 and PAK1 transcript levels and activity.
• A decrease in ARP2 protein levels and actin depolymerization were observed following 1α,25(OH)2D3 treatment.
• Pharmacological inhibition of RAC1 and PAK1 mimicked the actin polymerization-inhibiting effects of 1α,25(OH)2D3.

Conclusions:

• 1α,25(OH)2D3 disrupts the RAC1 and PAK1 signaling axis in endometrial carcinoma cells.
• This disruption leads to subsequent actin depolymerization, impacting cell structure and function.
• The findings suggest a role for vitamin D3 in modulating the actin cytoskeleton relevant to endometrial cancer progression.